BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer
BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...
Medscape1d
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
Managed Healthcare Executive12h
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
PharmExec1d
FDA Approves BeiGene’s Tevimbra for Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...
BioSpace1d
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
CURE1d
FDA Approves Tevimbra Plus Chemotherapy For Some With Esophageal Cancer
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
The American Journal of Managed Care1d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
BeiGene announces FDA approval of Tevimbra/chemotherapy combination
BeiGene (ONC) announced the U.S. FDA has approved Ttevimbra in combination with platinum-containing chemotherapy, for the first-line treatment ...
Precision Medicine Online1d
FDA Approves BeiGene's Tevimbra in First-Line PD-L1-Positive Esophageal Cancers
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
Fierce Pharma6d
BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...